Stockscreener 앱 받기
3.08
2.53%
-0.08
전일 마감가:
$3.16
열려 있는:
$3.15
하루 거래량:
989.85K
Relative Volume:
0.78
시가총액:
$157.40M
수익:
-
순이익/손실:
$-32.94M
주가수익비율:
-2.7748
EPS:
-1.11
순현금흐름:
$-24.95M
1주 성능:
+8.83%
1개월 성능:
+26.23%
6개월 성능:
+16.23%
1년 성능:
-29.20%
1일 변동 폭
$2.98
$3.17
1주일 범위
$2.77
$3.30
52주 변동 폭
$1.84
$5.31
Achieve Life Sciences Inc Stock (ACHV) Company Profile
명칭
Achieve Life Sciences Inc
전화
425-686-1500
주소
22722 29TH DR. SE, SEATTLE, BC
ACHV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
3.08 | 167.62M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-21 | 개시 | H.C. Wainwright | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2024-09-27 | 개시 | Raymond James | Strong Buy |
| 2023-05-10 | 재확인 | Maxim Group | Buy |
| 2021-06-23 | 개시 | Oppenheimer | Outperform |
Achieve Life Sciences Inc 주식(ACHV)의 최신 뉴스
Achieve Life Sciences (NASDAQ:ACHV) CMO Sells $76,532.33 in Stock - MarketBeat
Insider Selling: Achieve Life Sciences (NASDAQ:ACHV) Director Sells 139,858 Shares of Stock - MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Insider Sells $38,973.90 in Stock - MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Insider Sells $57,765.58 in Stock - MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Sees Large Growth in Short Interest - MarketBeat
Achieve Life Sciences (ACHV) Appoints Interim Chief Medical Officer - GuruFocus
Achieve Life Sciences (ACHV) Appoints Interim Chief Medical Offi - GuruFocus
Achieve Life Sciences appoints Mark Rubinstein as interim CMO By Investing.com - Investing.com Canada
Achieve Life Sciences appoints Mark Rubinstein as interim CMO - Investing.com
Achieve Life Sciences (ACHV) Appoints New Interim Chief Medical Officer - GuruFocus
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer - GlobeNewswire
Former UCSF Professor Takes CMO Role at Achieve Life Sciences Following FDA Filing Acceptance - Stock Titan
Achieve Life Sciences' nicotine dependence treatment under FDA review - MSN
Is Achieve Life Sciences Inc. stock influenced by commodity prices2025 Market Sentiment & Growth Oriented Trade Recommendations - Lancaster City Council
Xinos, Achieve Life Sciences CCO, sells $57,765 in ACHV stock By Investing.com - Investing.com Canada
Achieve Life Sciences Inc. Approaches Psychological Resistance LevelJuly 2025 Review & Growth Focused Stock Pick Reports - beatles.ru
Is Achieve Life Sciences Inc. a cyclical or defensive stockQuarterly Trade Review & Free Long-Term Investment Growth Plans - beatles.ru
Nantahala Capital Management LLC Has $2.40 Million Holdings in Achieve Life Sciences, Inc. $ACHV - MarketBeat
Volume spikes in Achieve Life Sciences Inc. stock – what they meanWeekly Market Outlook & Weekly High Return Stock Forecasts - Newser
Analyzing Achieve Life Sciences Inc. with risk reward ratio chartsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - Newser
Exit strategy if you’re trapped in Achieve Life Sciences Inc.July 2025 Summary & Low Drawdown Trading Strategies - Newser
Is Achieve Life Sciences Inc. forming a breakout pattern2025 Key Highlights & Verified Short-Term Trading Plans - خودرو بانک
How institutional ownership impacts Achieve Life Sciences Inc. stock2025 Bull vs Bear & Growth-Oriented Investment Plans - Newser
Can trapped investors hope for a rebound in Achieve Life Sciences Inc.Market Growth Summary & Stock Portfolio Risk Control - Newser
News impact scoring models applied to Achieve Life Sciences Inc.IPO Watch & Verified Entry Point Detection - Newser
Comparing Achieve Life Sciences Inc. in custom built stock radars2025 Earnings Impact & Free Technical Pattern Based Buy Signals - Newser
Will Achieve Life Sciences Inc. see short term momentum - Newser
Is Achieve Life Sciences Inc. showing signs of accumulationJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - Newser
Should you wait for a breakout in Achieve Life Sciences Inc.July 2025 Analyst Calls & Real-Time Market Sentiment Reports - Newser
Chart based analysis of Achieve Life Sciences Inc. trendsBull Run & Risk Managed Trade Strategies - Newser
Using portfolio simulators with Achieve Life Sciences Inc. included2025 Breakouts & Breakdowns & Community Shared Stock Ideas - Newser
Smart tools for monitoring Achieve Life Sciences Inc.’s price actionEarnings Risk Summary & Community Verified Watchlist Alerts - Newser
Achieve Life Sciences shares fall 1.75% premarket after FDA acceptance of cytisinicline NDA for smoking cessation. - AInvest
FDA accepts Achieve Life Sciences’ NDA for smoking cessation drug By Investing.com - Investing.com Canada
What is the target price for Achieve Life Sciences Inc. stockBuy Signal & Weekly High Conviction Ideas - خودرو بانک
Order flow analysis tools used on Achieve Life Sciences Inc.Weekly Gains Summary & Weekly Watchlist for Consistent Profits - Newser
Using flow based indicators on Achieve Life Sciences Inc.July 2025 Sentiment & Low Drawdown Momentum Trade Ideas - Newser
Achieve Life Sciences shares rise 1.36% after-hours after FDA acceptance of cytisinicline NDA for smoking cessation. - AInvest
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation - MarketScreener
FDA accepts Achieve Life Sciences’ NDA for smoking cessation drug - Investing.com
Achieve Life Sciences Says FDA Accepts Marketing Application for Smoking Cessation Drug - MarketScreener
Achieve Life Sciences announces FDA acceptance of cytisinicline new drug application for treatment of nicotine dependence for smoking cessation - MarketScreener
Achieve Life Sciences Announces FDA Acceptance of - GlobeNewswire
First New Smoking Cessation Drug in Two Decades: FDA to Review Achieve's Cytisinicline Treatment - Stock Titan
Real time breakdown of Achieve Life Sciences Inc. stock performance2025 Risk Factors & Consistent Growth Equity Picks - Newser
Should you avoid Achieve Life Sciences Inc. stock right nowJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - خودرو بانک
Achieve Life Sciences Inc (ACHV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):